Vertex Pharmaceuticals Inc (VRTX: NASDAQ)
$133.2 n/a | n/a%
04/24/15 - 03:59 PM ET
Portfolios with VRTX
- Portfolio NameUser Type
- ProAdage Capital
- ContributorMonster Momentum Stocks To ...
- ContributorBreakout Stocks Of The Week...
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
Latest VRTX Headlines from TheStreet
- Strong On High Relative Volume: Vertex Pharmaceuticals (VRTX) 04.21.15 | 10:04 am
- These 10 Pharma and Health Care Stocks Were the Worst S&P 500 Performers Last Quarter 04.02.15 | 11:04 am
- Vertex Pharmaceuticals (VRTX) Hits New Lifetime High Today 03.18.15 | 09:03 am
- Today's Unusual Social Activity Stock: Vertex Pharmaceuticals (VRTX) 03.05.15 | 09:03 am
- 3 Stocks Dragging In The Drugs Industry 03.04.15 | 12:03 pm
- What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results 02.23.15 | 11:02 am
- Insider Trading Alert - DAN, VRTX And ENSG Traded By Insiders 02.05.15 | 11:02 am
- Vertex Pharmaceuticals (VRTX) Downgraded From Hold to Sell 01.30.15 | 04:01 pm
- Vertex Pharmaceutical (VRTX) Stock Declines Today Following Earnings Realease 01.29.15 | 11:01 am
- Vertex Phamraceuticals (VRTX) Earnings Report: Q4 2014 Conference Call Transcript 01.29.15 | 09:01 am
Press Releases for VRTX
- Vertex To Announce First Quarter 2015 Financial Results On April 29 - Business Wire 04.09.15 | 04:04 pm
- Vertex Announces Data From 12-Week Phase 2 Safety Study Of VX-661 In Combination With Ivacaftor In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 03.23.15 | 07:03 am
- Vertex Receives U.S. Food And Drug Administration Approval Of KALYDECO® (ivacaftor) For Children With Cystic Fibrosis Ages 2 To 5 Who Have Specific Mutations In The CFTR Gene - Business Wire 03.18.15 | 07:03 am
- Vertex To Present At Upcoming Investor Conferences - Business Wire 02.11.15 | 04:02 pm
- Vertex Reports Full-Year And Fourth Quarter 2014 Financial Results And Provides Guidance For 2015 - Business Wire 01.28.15 | 04:01 pm
- Vertex Outlines 2015 Business Priorities To Support The Development, Approval And Launch Of New Medicines For The Treatment Of People With Cystic Fibrosis - Business Wire 01.11.15 | 08:01 pm
- Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2014 Financial Results - Business Wire 01.06.15 | 04:01 pm
- U.S. Food And Drug Administration Approves KALYDECO® (ivacaftor) For Use In People With Cystic Fibrosis Ages 6 And Older Who Have The R117H Mutation - Business Wire 12.29.14 | 03:12 pm
- David Altshuler, M.D., Ph.D., Joins Vertex As Executive Vice President Of Global Research And Chief Scientific Officer - Business Wire 12.15.14 | 09:12 am
- Vertex To Present At Deutsche Bank BioFEST On December 2 - Business Wire 11.20.14 | 04:11 pm
Partner Headlines for VRTX
- Gilead paying premium to buy Vertex not warranted right now, says Maxim - The Fly 04.21.15 | 01:04 pm
- Gilead should buy Vertex, says Bernstein - The Fly 04.21.15 | 08:04 am
- Vertex initiated with a Buy at Canaccord - The Fly 04.10.15 | 07:04 am
- PTC Therapeutics price target raised to $115 from $75 at Deutsche Bank - The Fly 04.09.15 | 07:04 am
- Vertex data not a surprise given recent commentary, says JPMorgan - The Fly 03.23.15 | 10:03 am
- Vertex weakness a buying opportunity, says Piper Jaffray - The Fly 03.23.15 | 10:03 am
- Vertex shares defended at CRT Capital - The Fly 03.23.15 | 09:03 am
- Obama seeks $215 million for 'precision medicine' - CNBC 01.30.15 | 06:01 am
- Drugmakers get mysterious invites to White House - CNBC 01.28.15 | 05:01 pm
- Obama Proposes U.S. Spending to Research Personalized Cures - Bloomberg 01.20.15 | 09:01 pm